Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X.
Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800–322–4349. The November 2011 monograph topics are on indacaterol, brentuximub vedotin, icatibant injection, aflibercept, and centruroides (Scorpion) immune F(ab′)2. The DUE/MUE is on indacaterol.
Get full access to this article
View all access options for this article.
References
1.
Dificid [package insert].San Diego, CA: Optimer Pharmaceuticals Inc; May 2011.
2.
BauerM.P.van DisselJ.T.KuijperE.J.Clostridium difficile: controversies and approaches to management. Curr Opin Infect Dis.2009; 22(6): 517–524.
3.
Cohen SH, Gerding DN, Johnson S, et al; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society of Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol.2010; 31(5): 431–455.
4.
tot PannerdenC.M.VerbonA.KuipersE.J.Recurrent Clostridium difficile infection: What are the treatment options?Drugs.2011; 71(7): 853–868.
5.
VenutoC.ButlerM.AshleyE.D.BrownJ.Alternative therapies for Clostridium difficile infections. Pharmacotherapy.2010; 30(12): 1266–1278.
6.
GerdingD.N.JohnsonS.Management of Clostridium difficile infection: thinking inside and outside the box. Clin Infect Dis.2010; 51(11): 1306–1313.
7.
Vancocin [package insert].Exton, PA: ViroPharma Inc; October 2005.
8.
AckermannG.LofflerB.AdlerD.RodloffA.C.In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother.2004; 48(6): 2280–2282.
9.
CreditoK.L.AppelbaumP.C.Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother.2004; 48(11): 4430–4434.
10.
FinegoldS.M.MolitorisD.VaisanenM.L.SongY.LiuC.BolanosM.In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother.2004; 48(12): 4898–4902.
11.
BiedenbachD.J.RossJ.E.PutnamS.D.JonesR.N.In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp. Antimicrob Agents Chemother.2010; 54(5): 2273–2275.
12.
SwansonR.N.HardyD.J.ShipkowitzN.L.In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrob Agents Chemother.1991; 35(6): 1108–1111.
13.
KarlowskyJ.A.LaingN.M.ZhanelG.G.In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother.2008; 52(11): 4163–4165.
14.
BabakhaniF.GomezA.RobertN.SearsP.Killing kinetics of fidaxomicin and its major metabolite (OP-1118) against Clostridium difficile [published online ahead of print February 24, 2011]. J Med M/crob/o/.10.1099/jmm.0.029470-0.
15.
TannockG.W.MunroK.TaylorC.A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology.2010; 156(pt 11): 3354–3359.
16.
ShueY.K.SearsP.S.ShangleS.Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother.2008; 52(4): 1391–1395.
17.
SearsP.LouieT.MullaneK.MillerM.ShueK.Pharmacokinetics/pharmacodynamics (PK/PD) of fidaxomicin in treatment of Clostridium difficile infection (CDI) [abstract]. In: Programs and abstracts from the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12–15, 2009; San Francisco, CA. Abstract A1–1949.
18.
BabakhaniF.SeddonJ.RobertN.ShueY.K.SearsP.Effects of inoculum, pH, and cations on the in vitro activity of fidaxomicin (OPT-80, PAR-101) against Clostridium difficile. Antimicrob Agents Chemother.2010; 54(6): 2674–2676.
19.
LouieT.J.EmeryJ.KrulickiW.ByrneB.MahM.OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother.2009; 53(1): 261–263.
20.
LouieT.MillerM.DonskeyC.MullaneK.GoldsteinE.J.Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial in patients with Clostridium difficile infection. Antimicrob Agents Chemother.2009; 53(1): 223–228.
21.
CitronD.M.BabakhaniF.GoldsteinE.J.Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection. Anaerobe.2009; 15(6): 234–236.
22.
GerdingD.SambolS.NagaroK.Restriction endonuclease analysis (REA) typing of Clostridium difficile in a phase 3 treatment trial of fidaxomicin vs. vancomycin: decreased cure rate for epidemic BI/NAP1/027 strain [abstract]. In: Programs and abstracts from the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12–15, 2009; San Francisco, CA. Abstract L1–1642.
23.
JohnsonS.CrookD.W.ComelyO.A.HighK.P.MillerM.GorbachS.L.Randomized clinical trial in Clostridium difficile infection confirms superiority of fidaxomicin over vancomycin [abstract]. Gastroenterology.2010; 139: e17.
24.
MillerM.A.MullaneK.M.WeissK.Faster time to resolution of diarrhea with fidaxomicin vs. vancomycin in patients with Clostridium difficile infection [abstract]. In: Programs and abstracts from the Infectious Disease Society of America 47th Annual Meeting; October 29-November 1, 2009; Philadelphia, PA. Abstract 422.
25.
GolanY.MullaneK.MillerM.Low recurrence rate among patients (pts) with C. difficile infection (CDI) treated with fidaxomicin (FDX). In: Programs and abstracts from the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12–15, 2009; San Francisco, CA. Abstract L1–1639.
26.
LouieT.J.MillerM.A.MullaneK.M.; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med.2011; 364(5): 422–431.
27.
MullaneK.M.CrookD.ComelyO.MillerM.A.ShueY.GorbachS.L.Use of concomitant antibiotics (CA) has a deleterious effect on outcomes during treatment for Clostridium difficile infection (CDI) [abstract]. In: Programs and abstracts from the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12–15, 2010; Boston, MA. Abstract K-1695.
28.
ComelyO.A.MillerM.LouieT.CrookD.SearsP.GorbachS.L.Randomized controlled trial (RCT) of fidaxomicin (FDX) versus vancomycin (VAN) in treatment of recurrent Clostridium difficile infection (CDI) [abstract]. In: Programs and abstracts from the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12–15, 2010; Boston, MA. Abstract L1–1305.
GorbachS.WeissK.SearsP.PullmanJ.Safety of fidaxomicin versus vancomycin in treatment of Clostridium difficile infection [abstract]. In: Programs and abstracts from the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12–15, 2009; San Francisco, CA. Abstract L1–1640.
